H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer

Poly(ADP-ribose) polymerase (PARP) inhibitors represent a promising strategy toward the treatment of triple-negative breast cancer (TNBC), which is often associated to genomic instability and/or BRCA mutations. However, clinical outcome is controversial and no benefits have been demonstrated in wild...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzucchelli, S., Truffi, M., Baccarini, F., Beretta, M., Sorrentino, L., Bellini, M., Rizzuto, M. A., Ottria, R., Ravelli, A., Ciuffreda, P., Prosperi, D., Corsi, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548799/
https://www.ncbi.nlm.nih.gov/pubmed/28790402
http://dx.doi.org/10.1038/s41598-017-07617-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548799/
https://www.ncbi.nlm.nih.gov/pubmed/28790402
http://dx.doi.org/10.1038/s41598-017-07617-7

Ejemplares similares